Lipopolysaccharides Upregulate Hepcidin in Neuron via Microglia and the IL-6/STAT3 Signaling Pathway

Molecular Neurobiology

Volumn 50, Issue 3, 2014, Pages 811-820

  Qian, Zhong Ming ^a   He, Xuan ^b   Liang, Tuo ^b   Wu, Ka Chun ^b   Yan, Yik Chun ^b   Lu, Li Na ^b   Yang, Guang ^a   Luo, Qian Qian ^a   Yung, Wing Ho ^b   Ke, Ya ^b  

^a FUDAN UNIVERSITY   (China)

^b Prince of Wales Hospital   (Hong Kong)

Author keywords

Brain iron; Cortex; Ferroportin 1 (Fpn1); Hepcidin; Interleukin 6 (IL 6); Lipopolysaccharides (LPS); Signal transducer and activator of transcription 3 (STAT3); Substantia nigra

Indexed keywords

HEPCIDIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; STAT3 PROTEIN;

ANIMAL; BRAIN CORTEX; CYTOLOGY; DRUG EFFECTS; MALE; METABOLISM; MICROGLIA; NERVE CELL; PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; UPREGULATION;

ANIMALS; CEREBRAL CORTEX; HEPCIDINS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; NEURONS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84896413655     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8671-3     Document Type: Article

References (61)

1. Qian ZM, Wang Q (1998) Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Rev 27:257–267
2. Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986–1995
3. Fleming RE, Sly WS (2002) Mechanisms of iron accumulation in hereditary hemochromatosis. Annu Rev Physiol 64:663–680
4. Hentze MW, Muckenthale MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117:285–297
5. Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26:323–342
6. Ganz T (2006) Hepcidin—a peptide hormone at the interface of innate immunity and iron metabolism. Curr Top Microbiol Immunol 306:183–198
7. Krause A, Neitz S, Magrert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K (2000) LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480:147–150
8. Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276:7806–7810
9. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O (2001) A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276:7811–7819
10. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S (2001) Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 98:8780–8785
11. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 99:4596–4601
12. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110:1037–1044
13. Lesbordes-Brion JC, Viatte L, Bennoun M, Lou DQ, Ramey G, Houbron C, Hamard G, Kahn A, Vaulont S (2006) Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 108:1402–1405
14. Nicolas G, Viatte L, Lou D-Q, Bennoun M, Beaumont C, Kahn A, Andrews NC, Vaulont S (2003) Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 34:97–101
15. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T (2005) Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 105:1797–1802
16. Hentze MW, Muckenthaler MU, Galy B, Camaschella C (2010) Two to tango: regulation of mammalian iron metabolism. Cell 142:24–38
17. Ganz T, Nemeth E (2011) Hepcidin and disorders of iron metabolism. Annu Rev Med 62:347–360
18. Du F, Qian C, Ming Qian Z, Wu X-M, Xie H, Yung W-H, Ke Y (2011) Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP-protein kinase a pathway. Glia 59:936–945
19. Li L, Holscher C, Chen B-B, Zhang Z-F, Liu Y-Z (2011) Hepcidin treatment modulates the expression of divalent metal transporter-1, ceruloplasmin, and ferroportin-1 in the rat cerebral cortex and hippocampus. Biol Trace Elem Res 143:1581–1593
20. Qian ZM, Shen X (2001) Brain iron transport and neurodegeneration. Trend Mol Med 7(3):103–108
21. Ke Y, Qian ZM (2003) Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2:246–253
22. Ke Y, Qian ZM (2007) Brain iron metabolism: neurobiology and neurochemistry. Prog Neurobiol 83(3):149–173
23. Wang Q, Du F, Qian Z-M, Ge XH, Zhu L, Yung WH, Yang L, Ke Y (2008) Lipopolysaccharide induces a significant increase in expression of iron regulatory hormone hepcidin in the cortex and substantia nigra in rat brain. Endocrinology 149:3920–3925
24. Wrighting DM, Andrews NC (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108:3204–3209
25. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU (2007) STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109:353–358
26. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, Ernst M, Klein C, Trautwein C (2007) STAT3 Is required for IL-6-gp130–dependent activation of hepcidin in vivo. Gastroenterology 132:294–300
27. Ke Y, Chang YZ, Duan XL, Du JR, Zhu L, Wang K, Yang XD, Ho KP, Qian ZM (2005) Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain. Neurobiol Aging 26(5):739–748
28. Du F, Z-m Q, Zhu L, Wu XM, W-h Y, T-y T, Ke Y (2009) L-DOPA neurotoxicity is mediated by up-regulation of DMT1 − IRE expression. PLoS ONE 4:e4593
29. Chang YZ, Qian ZM, Wang K, Zhu L, Yang XD, Du JR, Jiang L, Ho KP, Wang Q, Ke Y (2005) Effects of development and iron status on ceruloplasmin expression in rat brain. J Cell Physiol 204(2):623–633
30. Zechel S, Huber-Wittmer K, von Bohlen und Halbach O (2006) Distribution of the iron-regulating protein hepcidin in the murine central nervous system. J Neurosci Res 84:790–800
31. Bowman CC, Rasley A, Tranguch SL, Marriott I (2003) Cultured astrocytes express toll-like receptors for bacterial products. Glia 43(3):281–291
32. Zhou H, Lapointe BM, Clark SR, Zbytnuik L, Kubes P (2006) A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide. J Immunol 177(11):8103–8110
33. Rolls A, Shechter R, London A, Ziv Y, Ronen A, Levy R, Schwartz M (2007) Toll-like receptors modulate adult hippocampal neurogenesis. Nat Cell Biol 9(9):1081–1088
34. Shechter R, Ronen A, Rolls A, London A, Bakalash S, Young MJ, Schwartz M (2008) Toll-like receptor 4 restricts retinal progenitor cell proliferation. J Cell Biol 183(3):393–400
35. Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE, Rosenberg PA, Volpe JJ, Vartanian T (2002) The Toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 22:2478–2486
36. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, Vartanian T (2003) Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 100:8514–8519
37. Glezer I, Lapointe A, Rivest S (2006) Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries. FASEB J 20:750–752
38. Benicky J, Sánchez-Lemus E, Pavel J, Saavedra JM (2009) Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol 29(6–7):781–792
39. Crawford G, Le W, Smith R, Xie W, Stefani E, Appel S (1992) A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J Neurosci 12:3392–3398
40. Su Y, Zhang K, Schluesener HJ (2010) Antimicrobial peptides in the brain. Arch Immunol Ther Exp 58:365–377
41. Milatovic D, Zaja-Milatovic S, Montine KS, Shie FS, Montine TJ (2004) Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo. J Neuroinflammation 1(1):20. doi:10.1186/1742-2094-1-20
42. Montine TJ, Milatovic D, Gupta RC, Valyi-Nagy T, Morrow JD, Breyer RM (2002) Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem 83:463–470
43. Delgado M, Ganea D (2003) Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J 17:1922–1924
44. Urrutia P, Aguirre P, Esparza A, Tapia V, Mena NP, Arredondo M, González-Billault C, Núñez MT (2013) Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J Neurochem. doi:10.1111/jnc.12244
45. Oliveira-Filho JP, Badial PR, Cunha PH, Peiró JR, Araújo JP Jr, Divers TJ, Winand NJ, Borges AS (2012) Lipopolysaccharide infusion up-regulates hepcidin mRNA expression in equine liver. Innate Immunity 18:438–446
46. Marques F, Falcao AM, Sousa JC, Coppola G, Geschwind D, Sousa N, Correia-Neves M, Palha JA (2009) Altered iron metabolism is part of the choroid plexus response to peripheral inflammation. Endocrinology 150:2822–2828
47. Kim W-G, Mohney RP, Wilson B, Jeohn G-H, Liu B, Hong J-S (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20:6309–6316
48. Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151–170
49. Willard LB, Hauss-Wegrzyniak G, Wenk GL (1999) Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. Neuroscience 88:193–200
50. Kalman J, Engelhardt JI, Le WD, Xie W, Kovacs I, Kasa P, Appel SH (1997) Experimental immune-mediated damage of septal cholinergic neurons. J Neuroimmunol 77:63–74
51. Koistinaho M, Koistinaho J (2005) Interactions between Alzheimer's disease and cerebral ischemia—focus on inflammation. Brain Res Brain Res Rev 48(2):240–250
52. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T (2009) Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 87(3):181–194
53. von Bernhardi R (2010) Immunotherapy in Alzheimer's disease: where do we stand? Where should we go? J Alzheimers Dis 19(2):405–421
54. Centonze D, Finazzi-Agrò A, Bernardi G, Maccarrone M (2007) The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 28(4):180–187
55. Marek K, Jennings D (2009) Can we image premotor Parkinson disease? Neurology 72(7 Suppl):S21–S26
56. Long-Smith CM, Sullivan AM, Nolan YM (2009) The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 89(3):277–287
57. Stoll G, Jander S, Schroeter M (1998) Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol 56:149–171
58. Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, Tuomanen EI (1999) Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med 5:298–302
59. Streit WJ (2002) Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40:133–139
60. Town T, Nikolic V, Tan J (2005) The microglial “activation” continuum: from innate to adaptive responses. J Neuroinflammation 2:24. doi:10.1186/1742-2094-2-24
61. Sebai H, Gadacha W, Sani M, Aouani E, Ghanem-Boughanmi N, Ben-Attia M (2009) Protective effect of resveratrol against lipopolysaccharide-induced oxidative stress in rat brain. Brain Inj 23:1089–1094